Semaglutide (GLP-1 Receptor Agonist)
Treatment for Diabetes Mellitus Type 2
Typical Dosage: Oral: 3-14 mg daily; Injectable: 0.25-2 mg weekly
Effectiveness
90%
Safety Score
60%
Clinical Trials
27
Participants
100K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
Oral: 3-14 mg daily; Injectable: 0.25-2 mg weekly
Time to Effect
2-4 weeks for glucose, 2-3 months for full effect
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
1000(Treat 1000 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$13,000
Monitoring:$450
Side Effect Mgmt:$100
Total Annual:$13,550
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$80,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$17,371.79
Cost per Remission
$135,500
Comparison vs Sitagliptin
Cost Difference
+$8,000/year
More expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
No dominance
Semaglutide (GLP-1 Receptor Agonist) Outcomes
for Diabetes Mellitus Type 2
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+78%
Remission Rate
+10%
Common Side Effects
Nausea
+30%
Vomiting
+10%
Diarrhea
+15%
Constipation
+10%
Pancreatitis
+0.1%
Active Clinical Trials
10 active trials recruiting for Semaglutide (GLP-1 Receptor Agonist) in Diabetes Mellitus Type 2
Menopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Diabetes
NCT06715514RECRUITINGNA
96 participants
INTERVENTIONAL
Bern, Switzerland
Started: Feb 18, 2025
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
NCT05390892RECRUITINGPHASE4
6K participants
INTERVENTIONAL
Baltimore, United States +7 more
Started: Sep 26, 2022
Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists
NCT07325435ACTIVE NOT RECRUITINGPHASE4
60 participants
INTERVENTIONAL
Brooklyn, United States
Started: Dec 21, 2024
Gastric Emptying in Healthy Volunteers and GLP-1 Agonist Users
NCT06987669NOT YET RECRUITING
155 participants
OBSERVATIONAL
Started: May 17, 2025
Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass
NCT07272837NOT YET RECRUITING
25 participants
OBSERVATIONAL
Started: Jan 1, 2026
Pharmacogenetics of Response to GLP1R Agonists
NCT05071898RECRUITINGPHASE1
600 participants
INTERVENTIONAL
Lancaster, United States
Started: Apr 11, 2022
Effect of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Stimulation on Smoking Consumption in Type 2 Diabetes Patients
NCT06924697ENROLLING BY INVITATIONNA
46 participants
INTERVENTIONAL
Shanghai, China
Started: Jun 21, 2025
A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes
NCT07195994NOT YET RECRUITINGNA
90 participants
INTERVENTIONAL
London, Canada
Started: Jan 1, 2026
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
NCT06706284RECRUITINGPHASE4
50 participants
INTERVENTIONAL
San Antonio, United States +1 more
Started: Apr 11, 2025
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
NCT07309094RECRUITING
250 participants
OBSERVATIONAL
Valencia, Spain
Started: Sep 15, 2023
Completed Clinical Trials
4 completed trials for Semaglutide (GLP-1 Receptor Agonist) in Diabetes Mellitus Type 2
SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.
NCT05136287COMPLETED
140 participants
OBSERVATIONAL
Culleredo, Spain +10 more
Started: Feb 1, 2022
Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes
NCT06120556COMPLETED
130 participants
OBSERVATIONAL
Bari, Italy
Started: Jun 10, 2023
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
NCT03987919COMPLETEDPHASE3
1.88K participants
INTERVENTIONAL
Birmingham, United States +126 more
Started: Jul 30, 2019
Impact of Semaglutide on CD34+ EPC and Fat Derived MSC
NCT04126603COMPLETEDPHASE4
10 participants
INTERVENTIONAL
Washington D.C., United States +1 more
Started: Aug 1, 2019
Showing 20 of 32 total trials